The Cryptococcosis drugs in development market research report provides comprehensive information on the therapeutics under development for Cryptococcosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cryptococcosis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cryptococcosis and features dormant and discontinued products.

GlobalData tracks ten drugs in development for Cryptococcosis by ten companies/universities/institutes. The top development phase for Cryptococcosis is preclinical with eight drugs in that stage. The Cryptococcosis pipeline has eight drugs in development by companies and two by universities/ institutes. Some of the companies in the Cryptococcosis pipeline products market are: Pfizer, REYON Pharmaceutical and Stony Brook University.

The key targets in the Cryptococcosis pipeline products market include Dihydrofolate Reductase (DHFR or EC, Glucosylceramide (Glucocerebroside), and GPI Anchored Wall Transfer Protein 1 (PfGWT1 or EC 2.3.).

The key mechanisms of action in the Cryptococcosis pipeline product include Dihydrofolate Reductase (DHFR or EC Inhibitor with one drug in Preclinical. The Cryptococcosis pipeline products include three routes of administration with the top ROA being Inhalational and two key molecule types in the Cryptococcosis pipeline products market including Small Molecule, and Vaccine.

Cryptococcosis overview

Cryptococcosis is infection caused by Cryptococcus neoformans fungus. Symptoms include cough, fatigue, fever, headache, nausea, and skin rashes. Predisposing factors include a weakened immune system, such as due to HIV infection; high-dose of corticosteroids; cancer chemotherapy; or Hodgkin’s disease. Treatment includes antifungal drugs.

For a complete picture of Cryptococcosis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.